Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 30 studies | 36% ± 16% | |
| fibroblast | 20 studies | 31% ± 15% | |
| pericyte | 15 studies | 33% ± 12% | |
| smooth muscle cell | 15 studies | 35% ± 12% | |
| endothelial cell of artery | 13 studies | 30% ± 13% | |
| capillary endothelial cell | 12 studies | 27% ± 11% | |
| endothelial cell of vascular tree | 12 studies | 39% ± 17% | |
| vein endothelial cell | 10 studies | 40% ± 16% | |
| adipocyte | 8 studies | 29% ± 8% | |
| connective tissue cell | 7 studies | 29% ± 14% | |
| myofibroblast cell | 7 studies | 66% ± 10% | |
| endothelial cell of lymphatic vessel | 5 studies | 22% ± 4% | |
| pancreatic A cell | 3 studies | 36% ± 17% | |
| retina horizontal cell | 3 studies | 20% ± 5% | |
| mucus secreting cell | 3 studies | 26% ± 5% |
Insufficient scRNA-seq data for expression of LMCD1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 100% | 8130.77 | 458 / 459 | 99% | 24.21 | 1107 / 1118 |
| lung | 100% | 11480.79 | 577 / 578 | 97% | 11.63 | 1120 / 1155 |
| ovary | 98% | 4823.73 | 177 / 180 | 97% | 12.46 | 415 / 430 |
| uterus | 94% | 5327.58 | 159 / 170 | 84% | 12.10 | 386 / 459 |
| bladder | 95% | 8873.81 | 20 / 21 | 82% | 10.12 | 414 / 504 |
| skin | 79% | 4107.72 | 1422 / 1809 | 96% | 15.69 | 451 / 472 |
| prostate | 75% | 2748.77 | 183 / 245 | 86% | 7.13 | 433 / 502 |
| esophagus | 60% | 2101.63 | 870 / 1445 | 84% | 7.51 | 153 / 183 |
| stomach | 56% | 2834.61 | 202 / 359 | 86% | 7.44 | 247 / 286 |
| kidney | 53% | 1457.74 | 47 / 89 | 85% | 8.82 | 767 / 901 |
| thymus | 57% | 1262.19 | 375 / 653 | 67% | 4.16 | 406 / 605 |
| intestine | 29% | 1025.26 | 283 / 966 | 86% | 7.91 | 453 / 527 |
| pancreas | 5% | 125.52 | 18 / 328 | 98% | 22.67 | 175 / 178 |
| ureter | 0% | 0 | 0 / 0 | 100% | 7.12 | 1 / 1 |
| adipose | 100% | 10443.75 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 18640.44 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 96% | 15497.38 | 772 / 803 | 0% | 0 | 0 / 0 |
| spleen | 95% | 4506.55 | 228 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 93% | 10.27 | 42 / 45 |
| brain | 4% | 71.31 | 96 / 2642 | 87% | 6.96 | 612 / 705 |
| lymph node | 0% | 0 | 0 / 0 | 83% | 9.16 | 24 / 29 |
| heart | 79% | 3880.94 | 682 / 861 | 0% | 0 | 0 / 0 |
| liver | 3% | 113.30 | 6 / 226 | 68% | 5.53 | 276 / 406 |
| eye | 0% | 0 | 0 / 0 | 56% | 4.99 | 45 / 80 |
| adrenal gland | 7% | 140.20 | 17 / 258 | 43% | 3.18 | 99 / 230 |
| peripheral blood | 1% | 13.08 | 8 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0070886 | Biological process | positive regulation of calcineurin-NFAT signaling cascade |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0010611 | Biological process | regulation of cardiac muscle hypertrophy |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0003714 | Molecular function | transcription corepressor activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0008270 | Molecular function | zinc ion binding |
| Gene name | LMCD1 |
| Protein name | LIM and cysteine-rich domains protein 1 (Dyxin) LIM and cysteine rich domains 1 LIM and cysteine rich domains 1 (cDNA FLJ52480, highly similar to LIM and cysteine-rich domains protein 1) |
| Synonyms | |
| Description | FUNCTION: Transcriptional cofactor that restricts GATA6 function by inhibiting DNA-binding, resulting in repression of GATA6 transcriptional activation of downstream target genes. Represses GATA6-mediated trans activation of lung- and cardiac tissue-specific promoters. Inhibits DNA-binding by GATA4 and GATA1 to the cTNC promoter (By similarity). Plays a critical role in the development of cardiac hypertrophy via activation of calcineurin/nuclear factor of activated T-cells signaling pathway. . |
| Accessions | ENST00000157600.8 [Q9NZU5-1] ENST00000397386.7 ENST00000415597.5 C9IYS1 ENST00000456506.2 ENST00000426878.2 ENST00000454244.4 [Q9NZU5-2] H7C3D2 F8WB09 Q9NZU5 B4DEY6 |